Document is current
Any future updates will be listed below
-
Authors
Chi, Huanting https://orcid.org/0000-0002-2347-8782
Qu, Bingqian https://orcid.org/0000-0002-7330-2929
Prawira, Angga
Richardt, Talisa
Maurer, Lars
Hu, Jungen
Fu, Rebecca M
Lempp, Florian A https://orcid.org/0000-0001-6103-8078
Zhang, Zhenfeng
Grimm, Dirk https://orcid.org/0000-0001-6227-5665
Wu, Xianfang https://orcid.org/0000-0002-2995-935X
Urban, Stephan https://orcid.org/0000-0003-1560-8038
Dao Thi, Viet Loan https://orcid.org/0000-0003-2293-3592
-
Funding
Funding for this research was provided by:
Heidelberg University (SFB/TRR179)
Deutsche Forschungsgemeinschaft (272983813-SFB/TRR 179, 272983813-SFB/TRR 179, 240245660-SFB1129, 240245660-SFB1129)
Deutsches Zentrum für Infektionsforschung (05.704, 05.806, 05.823)
Foundation for the National Institutes of Health (DP2-AI170515)
Bundesministerium für Bildung und Forschung (VIRASCREEN 01KI211)
China Scholarship Council
- License Information
-
More Information
Article History
Received: 23 January 2024
Revised: 7 August 2024
Accepted: 22 August 2024
First Online: 4 September 2024
Disclosure and competing interests statement
: Stephan Urban is a co-inventor and applicant on patents protecting HBV pre-S1-derived lipopeptides (Myrcludex B/Bulevirtide/Hepcludex). The remaining authors declare no competing interests.
